Monopar Therapeutics Reports Strong Cash Position, Advances Late-Stage ALXN1840 Towards Mid-2026 NDA, and Expands Radiopharmaceutical Pipeline

summarizeSummary

Monopar Therapeutics' annual report highlights a robust cash position of $140.4 million, providing a runway through December 2027, and details significant progress across its clinical pipeline, including plans to submit an NDA for ALXN1840 in mid-2026 and advancements in its radiopharmaceutical programs.

check_boxKey Events

• Strong Financial Position

  Reported $140.4 million in cash, cash equivalents, and investments as of December 31, 2025, providing a liquidity runway through at least December 31, 2027.

• ALXN1840 NDA Submission Planned

  Expects to submit a New Drug Application (NDA) for ALXN1840, its late-stage Wilson disease candidate, in mid-2026, following positive long-term clinical data presentations and FDA interactions.

• Radiopharmaceutical Pipeline Advancement

  Progressed its MNPR-101-Zr imaging and MNPR-101-Lu therapeutic programs with ongoing Phase 1 clinical trials in Australia and received FDA IND clearance for MNPR-101-Lu on September 26, 2025.

• Strategic Leadership Appointment

  Appointed Susan Rodriguez as Chief Commercial and Strategy Officer, effective March 2, 2026, signaling preparation for future commercialization efforts.

auto_awesomeAnalysis

This 10-K filing provides a comprehensive update on Monopar Therapeutics' financial health and pipeline progress, indicating a strong operational trajectory. The company has secured a substantial cash runway through December 2027, significantly de-risking its operations as a clinical-stage biotech. A key highlight is the planned mid-2026 NDA submission for ALXN1840, its late-stage Wilson disease candidate, following positive long-term efficacy and safety data presentations. This is a critical step towards potential commercialization, especially given Alexion's prior termination of the program. Furthermore, the radiopharmaceutical pipeline, including MNPR-101-Zr and MNPR-101-Lu, is advancing with ongoing Phase 1 clinical trials in Australia and received FDA IND clearance for MNPR-101-Lu, demonstrating continued development in oncology. The appointment of a Chief Commercial and Strategy Officer underscores the company's strategic focus on future commercialization. While the company continues to incur operating losses, the strong liquidity and pipeline momentum are significant positive signals for investors.